Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Feb 18, 2010


Title: Use of Antisense Oligonucleotides or siRNA to Suppress Expression of eIF-5A1

Patent Number: 7,662,796

Filed: Nov. 28, 2005

Lead Inventor: John Thompson, Senesco Technologies

The invention "relates to apoptosis-specific eukaryotic initiation factor 5A … and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1," according to the patent's abstract. "The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A."

Title: siRNA Targeting Myeloid Differentiation Primary Response Gene 88

Patent Number: 7,662,950

Filed: Oct. 30, 2007

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MYD88."

Title: RNA Interference-Mediated Treatment of Alzheimer's Disease Using Short Interfering Nucleic Acid

Patent Number: 7,662,951

Filed: July 9, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent's abstract states, "concerns methods and reagents useful in modulating BACE gene expression in a variety of applications, including use in therapeutic, diagnostic, target-validation, and genomic-discovery applications. Specifically, the invention relates to small nucleic acid molecules … capable of mediating RNA interference against beta-secretase, amyloid precursor protein, pin-1, presenillin 1, and/or presenillin 2 gene expression and/or activity. The small nucleic acid molecules are useful in the treatment of Alzheimer's disease and any other condition that responds to modulation of BACE, APP, pin-1, PS-1, and/or PS-2 expression or activity."

Title: RNA Interference-Mediated Inhibition of GRB2-Associated Binding Protein Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 7,662,952

Filed: Sept. 2, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating GRB2-associated binding protein gene expression using short interfering nucleic acid molecules," the patent's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of GRB2 associated binding protein gene expression and/or activity by RNA interference using small nucleic acid molecules … [which] are useful in the treatment of cancer, malignant blood disease (leukemia), inflammatory diseases or conditions, allergic diseases or conditions, or proliferative diseases or conditions."

Title: Triggered RNAi

Application Number: 20100035233

Filed: May 22, 2009

Lead Inventor: Peng Yin, California Institute of Technology

The patent application, its abstract states, "relates to methods and compositions for triggering RNAi. Triggered RNAi is highly versatile because the silencing targets are independent of the detection targets. In some embodiments, methods of silencing or modulating the expression of a marker gene are provided.

"The methods generally comprise providing an initiator to a cell comprising a detection target and a silencing target gene, wherein the detection target is different from the silencing target gene, [and the] binding of the detection target to the initiator initiates formation of an inactivator double-stranded RNA," the abstract adds. "The inactivator dsRNA can silence the silencing target gene to modulate the expression of a marker gene."

Title: siRNA Inhibition of P13K, P85, PA110, AKT2 and Methods of Use

Application Number: 20100035965

Filed: May 18, 2007 PCT Filed: May 18, 2007

Lead Inventor: Mark Evers, University of Texas Medical Branch

The invention, the patent application's abstract states, "provides polynucleotides, compositions including polynucleotides, and the uses thereof for treating cancer in a subject. The polynucleotides silence the expression of coding regions that encode polypeptides such as p85-alpha, p110-alpha, and Akt2. The cancers treatable using the methods described herein include colorectal cancer, breast cancer, lung cancer, and metastases thereof."

Title: Nucleic Acid Molecules and Collections Thereof, Their Application, and Modification

Application Number: 20100035760

Filed: Jan. 10, 2007 PCT Filed: Jan. 10, 2007

Lead Inventor: Ronald Plasterk, Hubrecht Laboratory

"The invention provides a method for characterizing a sample comprising nucleic acid derived from a cell," the patent application's abstract states. "The method comprises determining whether a sample comprises at least a minimal sequence of at least one new microRNA according to the invention or a mammalian ortholog thereof, and characterizing the sample on the basis of the presence or absence of the miRNA. The invention further provides nucleic acid molecules and collections thereof and their use in therapeutic and diagnostic applications. The invention furthermore provides a method for identifying a miRNA molecule or a precursor molecule thereof."

Title: Methods and Compositions for Regulating Cell Cycle Progression

Application Number: 20100035966

Filed: June 14, 2007 PCT Filed: June 14, 2007

Lead Inventor: Peter Linsley, Rosetta Inpharmatics (Merck)

The patent application, its abstract states, claims "a method … of inhibiting proliferation of a mammalian cell [by] introducing into said cell an effective amount of at least one small interfering RNA agent [that] comprises a nucleotide sequence of at least 15 nucleotides" of a pre-defined sequence.

"In some embodiments, the method comprises introducing at least one [RNAi agent] that inhibits the expression of at least one miR-16 responsive gene," the abstract adds.

Title: Mediated Cellular Delivery of LNA Oligonucleotides

Application Number: 20100035968

Filed: Jan. 18, 2008

Lead Inventor: Soeren Vestergaard Rasmussen, Exiqon

The invention "relates to novel modified oligomeric compounds and to methods of making and using such compounds," the patent application's abstract states. "The invention further relates to methods of enhancing the cellular uptake of oligomeric compounds comprising conjugating a metal chelator to those."

Title: RNAi Inhibition of CTGF for Treatment of Ocular Disorders

Application Number: 20100035969

Filed: Oct. 12, 2009

Lead Inventor: Allan Shepard, Alcon

The patent application, its abstract states, claims "RNA interference … for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy, and wound healing. Such disorders are treated by administering interfering RNAs."

Title: Compositions Comprising an siRNA and Lipidic 4,5-Disubstituted 2-Deoxystreptamine Ring Aminoglycoside Derivatives and Uses Thereof

Application Number: 20100035974

Filed: Oct. 4, 2007 PCT Filed: Oct. 4, 2007

Lead Inventor:
Jean-Marie Lehn, Centre National De La Recherche Scientifique

The invention relates to a "composition comprising a siRNA and a transfecting compound consisting of an aminoglycoside of the class of 4,5-disubstituted 2-deoxystreptamine ring linked via a spacer molecule to a lipid moiety" of a pre-defined formula, the patent application's abstract states. "The invention also concerns in vitro and in vivo applications of these compositions."

Title: Biodegradable Poly-Beta-Amino Esters and Uses Thereof

Application Number: 20100036084

Filed: July 23, 2009

Lead Inventor: Robert Langer, Massachusetts Institute of Technology

"Poly-beta-amino esters prepared from the conjugate addition of bis(secondary amines) or primary amines to a bis(acrylate ester) are described," the patent application's abstract states. "Methods of preparing these polymers from commercially available starting materials are also provided.

"These tertiary amine-containing polymers are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the poly-amine nature of these polymers, they are particularly suited for the delivery of polynucleotides," the abstract notes.
"Nanoparticles containing polymer/polynucleotide complexes have been prepared. The inventive polymers may also be used to encapsulate other agents to be delivered. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings."

Title: RNA Interference Compositions and Methods

Application Number: 20100036107

Filed: Oct. 13, 2009

Lead Inventor: Gary Clawson, Pennsylvania State University

"The invention provides isolated nucleic acids," the patent application's abstract states. "For example, the invention provides isolated nucleic acids having at least one strand with both sense and antisense sequences that are complementary to each other. The invention also provides isolated nucleic acids having at least one strand that is a template for both sense and antisense sequences that are complementary to each other. In addition, the invention provides cells, viruses, and transgenic animals containing one or more of the isolated nucleic acids provided herein, as well as methods for using one or more of the isolated nucleic acids provided herein to reduce the level of an RNA within a cell."

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.